Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

regardless of the number of active HIV drugs in a patient's background therapy."

The study, known as VICTOR-E1 (Vicriviroc in Combination Treatment with Optimized Antiretroviral Therapy Regimen in Experienced Subjects), evaluated the safety and efficacy of vicriviroc (30 mg or 20 mg once daily) in combination with an optimized ritonavir-boosted, protease inhibitor-containing antiretroviral regimen compared to a control group receiving new OBT alone. The primary endpoint of the study was change in HIV-RNA at week 48. A total of 116 treatment-experienced adult HIV-infected patients with R5-type virus at screening were randomized in this placebo-controlled, double-blind study at 37 sites throughout Europe, South Africa and North and South America.

Results of the study through 48 weeks demonstrated potent and sustained viral suppression in the vicriviroc arms, with significantly greater decreases in mean HIV-RNA, as well as greater increases in mean CD4 counts, compared to the control arm. At 48 weeks, patients in the 30 mg and 20 mg vicriviroc treatment groups achieved mean decreases from baseline in viral load of -1.77 and -1.75 (log10 copies/mL), respectively, compared to -0.79 for the control group (p=0.0017 and p=0.0026, respectively). Mean increases from baseline in CD4 cell counts in the vicriviroc groups were +102 and +134 (cells/mm3), respectively, compared to +65 in the control group. Fewer patients in the vicriviroc groups discontinued from the study due to virologic failure compared to those in the control group (13 percent and 8 percent vs. 38 percent, respectively).

No clinically relevant differences in safety profile between the vicriviroc and control groups were observed in this study, including liver toxicity, opportunistic infections, malignancies or other conditions. There were no cases of grade 3/4 elevated ALT reported in the vicriviroc groups compared to one case in the control group, and there were one, two and one cases of g
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...igher mortality and lower surgery rates in women v...akage may be related to the complexity of evaluati... findings of a Mayo Clinic study published this mo...al valve prolapse affects approximately 150 millio...ery, preferably valve repair rather than replaceme...
(Date:12/1/2008)...HICON, Inc., a Johnson & Johnson company, anno...of its Professional Wound Care business to One Equ...are not being disclosed. , , Under the term...ired the Professional Wound Care product portfolio...s PROMOGRAN Matrix Wound Dressing, TIELLE Hydropol...
(Date:12/1/2008)...itute,s cancer registry has found that as many as ...mplete radiation treatment following breast-conser...ad to worse outcomes. , Dr. Heather Taffet Gold ...und that among a nationally representative sample ...ed 65 and older, almost 1,300 women experienced de...
(Date:12/1/2008)... -- The Food Allergy & Anaphylaxis Network (FA...ew CEO, replacing Founder Anne Munoz-Furlong, who ...N extensive knowledge of anaphylaxis, a severe, po...x years, as Senior Director of Marketing, she led ...Dey Pharmaceutical products, including EpiPen(R), ...
Breaking Medicine News(10 mins):Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:FAAN Names New CEO 2
...rnataka insist on a HIV certificate from the forei...datory//. The Visvesvaraya Technological Universit...eges in the state. It has issued strict orders no.../NRI students during admissions. K Balaveera Reddy...
...s have said that they planned to begin restocking ... Livestock Breeding and Veterinary department in ...u as also the subsequent culling program would be ...oultry feed, while keeping such areas under close ...
... have issued a warning to the public that they cou...rescription drugs through the Internet//. Drugs ... from foreign websites, have often turned out to.... Nigel Strick, the council's trading standards ma...
...d on Thursday in favour of a group of South Africa...partment// must immediately remove restrictions on...ment for the prisoners. The case was brought on b...a Gabriel, who represented the prisoners and the T...
Other Medicine News:
(Date:11/30/2008)...wswire-USNewswire/ -- Abnormalities in auditory an... with autism spectrum disorder by using magnetoenc... today at the annual meeting of the Radiological S...MEG, we can record the tiny magnetic fields associ... Roberts, Ph.D., vice chair of research in the Dep...
(Date:11/27/2008)...ajority of acute lymphoblastic leukemia relapse ca...of diagnosis , , MEMPHIS, Tenn., Nov. 27 /P...ildren,s Research Hospital have identified distinc...en with acute lymphoblastic leukemia (ALL) that ca...ning treatments for ALL relapse in children and, u...
(Date:11/26/2008)... Subjects , , FRANKLIN, Mass., Nov. 26 /PRN...in Board: PLCSF) announced today that it has recei...nistration (FDA) for its U.S. pivotal trial to stu...ystem(TM) and associated therapy in the preventio... The FDA also approved PLC,s request to expand th...
(Date:11/25/2008)...espondents against expanding statin use broadly in...LS, N.J., Nov. 25 JUPITER, a clini...rdiovascular risk of healthy patients with elevate...lder adults, according to a national poll directed...took part in the online poll conducted by medical ...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 1Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 2Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 4Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 1Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 2Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 3Nanodrop test tubes created with a flip of a switch 2902 1Nanodrop test tubes created with a flip of a switch 2902 2Covenant House Welcomes His Holiness Pope Benedict XVI 16888 1
...ts Success with Positive Phase IIa Clinical,Trial ...New Application of Key,Product in AM-Pharma,s Pipe...arma B.V., the,biopharmaceutical company developin...mmatory diseases, today announced the positive,cli...e (AP) trial,for patients with ulcerative colitis,...
...etts, July 08, 2007 /PRNewswire/ -- , - ENDORSE Gl...ment Hospital-Wide Strategies to Optimize VTE Mana... and Provide Appropriate,prophylaxis to Prevent VT...g hospital,patients and most of these at-risk pati...ccording to data from the international,ENDORSE (E...
Other Medicine Technology:AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 2International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 3International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 4
...isticated lathing techniques, intrinsically permea...hinsite lenses feature a center thickness of just ... powered Thinsite lenses maintain a 30% decrease i...ue design eliminates stress points to reduce the c...
Lifestyle Gp is a simultaneous vision lens with patented multi-aspheric back surface. Through a series of front and back surface curves, the LifeStyle Gp delivers up to +3.00 diopters of add. Plus, i
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach.
Medicine Products: